Elekta AB (OTCMKTS:EKTAY - Get Free Report) traded down 1.8% during trading on Thursday . The stock traded as low as $5.04 and last traded at $5.04. 909 shares changed hands during mid-day trading, a decline of 70% from the average session volume of 3,064 shares. The stock had previously closed at $5.13.
Wall Street Analyst Weigh In
EKTAY has been the subject of several recent research reports. UBS Group initiated coverage on shares of Elekta in a research report on Wednesday, September 3rd. They issued a "sell" rating for the company. Zacks Research upgraded shares of Elekta from a "strong sell" rating to a "hold" rating in a report on Tuesday, September 16th. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Reduce".
Read Our Latest Analysis on EKTAY
Elekta Trading Down 1.8%
The company has a current ratio of 1.05, a quick ratio of 0.82 and a debt-to-equity ratio of 0.63. The company's fifty day moving average is $5.01 and its 200-day moving average is $5.04. The firm has a market capitalization of $1.86 billion, a P/E ratio of 84.01 and a beta of 1.12.
Elekta (OTCMKTS:EKTAY - Get Free Report) last posted its quarterly earnings data on Thursday, August 28th. The company reported $0.03 earnings per share (EPS) for the quarter. Elekta had a net margin of 1.40% and a return on equity of 11.49%. The business had revenue of $379.64 million during the quarter. As a group, sell-side analysts anticipate that Elekta AB will post 0.36 earnings per share for the current fiscal year.
Elekta Announces Dividend
The firm also recently announced a dividend, which was paid on Friday, September 26th. Investors of record on Tuesday, September 9th were paid a dividend of $0.0744 per share. The ex-dividend date was Monday, September 8th. This represents a yield of 289.0%. Elekta's dividend payout ratio is presently 216.67%.
About Elekta
(
Get Free Report)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elekta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elekta wasn't on the list.
While Elekta currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.